Recently, Zacks.com users have been paying close attention to Vertex (VRTX). This makes it worthwhile to examine what the stock has in store. We recently published a list of Jim Cramer Discusses ...

Vertex has doubled down on cell-based therapies for type 1 diabetes (T1D), buying ViaCyte in a $320 million deal that it says will accelerate development of its own candidate VX-880. The deal has ...

“The number of conscientious, accurate, fact-reporting, responsible journalists is diminishing. Those that exist must be supported. A functioning democracy cannot flourish with them and the ...

After a vote Thursday, the acting chair of the SEC described The Enhancement and Standardization of Climate-Related Disclosures for Investors as “unnecessarily intrusive.” ...